Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "biopharma"

762 News Found

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report
News | February 26, 2025

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain


Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis
Clinical Trials | February 07, 2025

Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis

Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo


Biocon’s S&P Global ESG Score improves to 69 for 2024
Sustainability | January 30, 2025

Biocon’s S&P Global ESG Score improves to 69 for 2024

Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53


OneSource receives EIR with VAI classification from USFDA for BLD facility
Drug Approval | January 29, 2025

OneSource receives EIR with VAI classification from USFDA for BLD facility

OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies


Indegene wins 2025 BIG Innovation Award for Hyper-automated AI solution
News | January 18, 2025

Indegene wins 2025 BIG Innovation Award for Hyper-automated AI solution

Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform


Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107
Clinical Trials | January 09, 2025

Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107

The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs


Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease
Drug Approval | January 07, 2025

Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease

Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A


Veeda Group rebrands as Veeda Lifesciences
News | January 03, 2025

Veeda Group rebrands as Veeda Lifesciences

The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise


Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA
Drug Approval | January 02, 2025

Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA

DOVBLERON marks the 13th addition to Innovent’s commercial portfolio